Bacterial lysate - Lallemand Pharma

Drug Profile

Bacterial lysate - Lallemand Pharma

Alternative Names: Antibacterial vaccine sublingual - Lallemand Pharma; Bactovax; Bromunyl; Immubron; Ismigen; PIR-05; PMBL - Lallemand Pharma; Polyvalent Bacterial Mechanical Lysate - Lallemand Pharma; Provax; Pulmigen; Respibron; Sublingual antibacterial vaccine - Lallemand Pharma

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lallemand Pharma
  • Class Antibacterials; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Respiratory tract infections
  • Phase III Allergic asthma

Most Recent Events

  • 11 May 2017 Phase-III development for Allergic asthma (In adolescents, In children) is ongoing in Poland (Sublingual) (Lallemand Pharma website, May 2017)
  • 24 Mar 2014 No development reported - Preregistration for Respiratory tract infections in Russia (Sublingual)
  • 09 Sep 2013 Phase-III clinical trials in Allergic asthma (in children and adolescents) in Poland (Sublingual) (EudraCT2013-000737-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top